Premier Alternatives

CytoAgents

Pittsburgh, PA · Founded 2018 · Privately Held (backing)

Developer of pharmaceutical drugs designed to treat cytokine release syndrome. CytoAgents is based in Pittsburgh, PA and was founded in 2018. It was valued at $52 million at its later-stage round in May 2023, the last priced event on record. It has raised $38.6 million across 2 recorded rounds; the latest was a $7 million early-stage round in May 2023.

PMV mark · valuation
$52.0M
Oct 2026
Priced at
its later-stage round
May 2023
Total raised
$38.6M
Last round
Early Stage VC
May 2023

CytoAgents key facts

as of Oct 2026
  • Developer of pharmaceutical drugs designed to treat cytokine release syndrome.
  • CytoAgents is valued at approximately $52.0M as of Oct 2026, set at its later-stage round, May 2023; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $38.6M across 2 recorded rounds; the latest was Early Stage VC ($7.0M) in May 2023.
  • Notable investors include National Institutes of Health, Innovation Works, Richard King Mellon Foundation, AlphaLab Health, BlueTree Allied Angels — 15 tracked in total.
  • CytoAgents has filed 2 Form Ds with the SEC since 2021, most recently May 2023 ($7.0M sold to 23 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$52.0M

Valued at $52.0M at its later-stage round, May 2023. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of CytoAgents with a free account
  • ·The complete investor list: 15 names
  • ·Watch CytoAgents: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

CytoAgents funding rounds

2 rounds
May 2023Early Stage VC$7.0MSEC filing▮
Jul 2021Early Stage VC$6.1MSEC filing▮
Full funding history →

CytoAgents valuation

CytoAgents was valued at $52 million at its later-stage round in May 2023. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has CytoAgents raised?

CytoAgents has raised $38.6 million in total; 2 of its rounds are on record. The largest on record was a $7 million early-stage round in May 2023.

CytoAgents has filed 2 Form Ds with the SEC since 2021, most recently in May 2023 ($7 million sold to 23 investors).

CytoAgents investors

15 investors are on record for CytoAgents, including National Institutes of Health, Innovation Works, Richard King Mellon Foundation and AlphaLab Health. The early-stage round in May 2023 drew 23 investors.

About CytoAgents

Developer of pharmaceutical drugs designed to treat cytokine release syndrome. The company's drugs develop a broadly accessible treatment for multiple indications of high unmet need, including oncology CAR-T cell therapy, COVID-19, and respiratory epidemics, enabling physicians to effectively treat patients suffering from CRS through a novel approach by calming the natural immune response to a multi-organ disease.

Sector
Healthcare
HQ
Pittsburgh, PA, United States
Founded
2018
Employees
10
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.